InMed Pharmaceuticals Inc. (IMLFF)

InMed Pharmaceuticals was incorporated in the year 1981. It is a pre-clinical stage biopharmaceutical company having the concept of R & D of the researches and cannabinoid-based therapies. The company has its headquarters in Vancouver, Canada with the variety of treatments having cannabis as the major platform. The company’s leading product is INM-750 and Pharmaseed Ltd has made a mutual agreement with the company to develop the formulation of the drug for treating EB (Epidermolysis Bullosa), wound-healing and other dermatological applications. The company deals with the targeted therapy with the intent of modification of the cause of the disease in certain patients suffering from EB Simplex and the treatment of the major symptoms of the EB problem. These diseases are handled with the aim of reduced pain, itching, healing and providing an antimicrobial approach. INM-750 has an impact on the underlying disease with the increased production of the keratins (proteins) in the skin area.

The research for INM-085 is under progress for treating the problems like dermatology, pain, inflammation, arthritis, cancer and other chronic diseases. The company is working on the concept of development of 3-D human skin models of EB for evaluation of the drug efficiency of its medications. The company had its former name as Cannabis Technologies Inc. and it changed the name in 2014. The majority of the R&D companies using cannabis revolves around the active ingredient ‘Cannabinoids’. This along with Tetrahydrocannabinol is the compound found in cannabis plant which is used to craft medicines. The company is a pre-clinical stage biopharma group specializing in the new therapies introduced through intensive research along with the innovative drug delivery systems.

The company is gaining a strong name in the medical industry. Its drug development pipeline with cannabinoid biosynthesis technology is the major aspect in driving the fundamental value to the company. The bioinformatics database drug and disease targeting tool are used by the company to make the best value of medicines to the products. The 52-week stock price range of the company is $0.28 – $1.95. The stocks are blooming with the new researches being introduced by the team of medical experts. It is expected that the company gets the best responsiveness with the new conceptual medicines being introduced.

In the recent news, this company has made an announcement for the filing of Patent Cooperation Treaty (PCT) application having the proprietary program for biosynthesis for the manufacturing of cannabinoids similar to the natural options available. It is a major step for the company and the conversion of the patient application will be positive for the protection of biosynthesis platform of technology. It will ultimately protect the efforts for modulation of the internal machinery for increasing the metabolites required for the biosynthesizing of the cannabinoid. The company is actively making the moves to manufacture cannabinoids through the process of biosynthesis. The experts and the medical team are looking for the resourceful investments to give the required results to the medical field. It will be a great move for the company and the investors will benefit from the patent coverage through the global patenting of the coverage of the products.